Market forces rained on the parade of Wave Life Sciences Ltd. (NASDAQ:WVE) shareholders today, when the analysts downgraded their forecasts for this year. This report focused on revenue estimates, and it looks as though the consensus view of the business has become substantially more conservative. The stock price has risen 6.3% to US$6.10 over the past week. Investors could be forgiven for changing their mind on the business following the downgrade; but it's not clear if the revised forecasts will lead to selling activity.

Following the downgrade, the consensus from 16 analysts covering Wave Life Sciences is for revenues of US$52m in 2026, implying a painful 20% decline in sales compared to the last 12 months. Per-share losses are expected to see a sharp uptick, reaching US$1.14. Yet before this consensus update, the analysts had been forecasting revenues of US$59m and losses of US$1.14 per share in 2026. So there's definitely been a change in sentiment in this update, with the analysts administering a substantial haircut to this year's revenue estimates, while at the same time holding losses per share steady.

The consensus price target fell 13% to US$19.06, with the analysts clearly concerned about the weaker revenue outlook and expectation of ongoing losses.

Another way we can view these estimates is in the context of the bigger picture, such as how the forecasts stack up against past performance, and whether forecasts are more or less bullish relative to other companies in the industry. We would highlight that sales are expected to reverse, with a forecast 36% annualised revenue decline to the end of 2026. That is a notable change from historical growth of 22% over the last five years. Compare this with our data, which suggests that other companies in the same industry are, in aggregate, expected to see their revenue grow 9.1% per year. It's pretty clear that Wave Life Sciences' revenues are expected to perform substantially worse than the wider industry.

The Bottom Line

Unfortunately analysts also downgraded their revenue estimates, and industry data suggests that Wave Life Sciences' revenues are expected to grow slower than the wider market. The consensus price target fell measurably, with analysts seemingly not reassured by recent business developments, leading to a lower estimate of Wave Life Sciences' future valuation. Given the stark change in sentiment, we'd understand if investors became more cautious on Wave Life Sciences after today.

With that said, the long-term trajectory of the company's earnings is a lot more important than next year. We have estimates - from multiple Wave Life Sciences analysts - going out to 2028, and you can see them free on our platform here.

Of course, seeing company management invest large sums of money in a stock can be just as useful as knowing whether analysts are downgrading their estimates. So you may also wish to search this free list of stocks with high insider ownership.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.